PEPD

Xaa-Pro dipeptidase · P12955 · PEPD on Sugi Atlas →

12,344 patent compounds predicted against PEPD, 8,298 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL683116	0.71	3/20
SCHEMBL1506214	0.56	3/20
SCHEMBL1506217	0.56	3/20
SCHEMBL682288	0.52	3/20
SCHEMBL683446	0.51	3/20
SCHEMBL737851	0.46	3/20
Hydrochloric Acid (SCHEMBL737850)	0.44	3/20
Hydrochloric Acid (SCHEMBL541147)	0.38	3/20
Daunorubicin (SCHEMBL3041)	1.00	2/20
Doxorubicin (SCHEMBL3243)	1.00	2/20
Epirubicin (SCHEMBL8582)	1.00	2/20
Epirubicin (SCHEMBL95415)	1.00	2/20
Epirubicin (SCHEMBL233853)	1.00	2/20
Daunorubicin (SCHEMBL289431)	1.00	2/20
Daunorubicin (SCHEMBL319903)	1.00	2/20
Epirubicin (SCHEMBL443112)	1.00	2/20
Daunorubicin (SCHEMBL562720)	1.00	2/20
Doxorubicin (SCHEMBL570680)	1.00	2/20
Epirubicin (SCHEMBL774188)	1.00	2/20
Epirubicin (SCHEMBL1021464)	1.00	2/20

Clinical trials — most relevant to PEPD by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of DPP4 Inhibition on Vasoconstriction	PHASE4	COMPLETED
Papillary Epinephrine Injection Combined With Rectal Indomethacin	PHASE4	COMPLETED
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats	PHASE4	COMPLETED
Incretins in Impaired Fasting Glucose	PHASE4	COMPLETED
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)	PHASE4	COMPLETED
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes	PHASE3	COMPLETED
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes	PHASE3	COMPLETED
Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop System	PHASE3	COMPLETED
Linagliptin Add-on to Insulin Background Therapy	PHASE3	COMPLETED
Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients	PHASE3	ENROLLING_BY_INVITATION
Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis	PHASE1/PHASE2	COMPLETED
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency	PHASE2	COMPLETED
Prevention of Cardiac Dysfunction During Breast Cancer Therapy	PHASE2	COMPLETED
GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis	PHASE2	COMPLETED
Effect of Aspergillus Niger Prolyl Endoprotease (AN-PEP) Enzyme on the Effects of Gluten Ingestion in Patients With Coeliac Disease	PHASE1/PHASE2	COMPLETED
Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis	PHASE1	COMPLETED
Protein Digestion and Amino Acid Absorption in the Aging Gastrointestinal Tract	nan	COMPLETED
DPP4 Activity, Microvascular Reactivity and Inflammation	nan	COMPLETED
Acute Pancreatitis Targets (APT) Study	nan	COMPLETED
Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding	nan	COMPLETED
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.	nan	COMPLETED
Perioperative Sitagliptin Medication for Reduction of the Inflammatory Response Associated With Cardiopulmonary Bypass	nan	COMPLETED
Utility of Trypsinogen -2 in Early Detection and Follow Up of Post-pancreatectomy Acute Pancreatitis (PPAP)	nan	RECRUITING
Markers in Acute Pancreatitis-1	nan	COMPLETED
Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients	nan	COMPLETED
Effects of P24 on Postprandial Aminoacidemia	nan	NOT_YET_RECRUITING
Clearance of Vasoactive Metabolites With Blood Purification	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PEPD binder may also engage these)

Protein	Name	Similarity
Q5RFB3	—	1.000	Q5RFB3 →
Q5I0D7	—	1.000	Q5I0D7 →
Q11136	—	1.000	Q11136 →
C5G874	—	0.994	C5G874 →
C1H9Q9	—	0.992	C1H9Q9 →
C5PHM7	—	0.990	C5PHM7 →
Q55E60	—	0.990	Q55E60 →
C4JF09	—	0.990	C4JF09 →
C5JQ04	—	0.990	C5JQ04 →
C0NIF0	—	0.989	C0NIF0 →
C6H7R7	—	0.987	C6H7R7 →
C7YVN8	—	0.987	C7YVN8 →
A1DG66	—	0.987	A1DG66 →
Q4X267	—	0.987	Q4X267 →
C1GD57	—	0.986	C1GD57 →
E9EUE6	—	0.986	E9EUE6 →
B0DZL3	—	0.986	B0DZL3 →
E9DDK8	—	0.986	E9DDK8 →
C4JY72	—	0.986	C4JY72 →
E9E9B2	—	0.985	E9E9B2 →
Q4WRV9	—	0.985	Q4WRV9 →
C0SHQ0	—	0.985	C0SHQ0 →
B8NC10	—	0.984	B8NC10 →
E9E2J4	—	0.984	E9E2J4 →
Q0CFZ0	—	0.984	Q0CFZ0 →
Q9SLN5	—	0.984	Q9SLN5 →
C1H3X3	—	0.984	C1H3X3 →
E9F9J8	—	0.984	E9F9J8 →
B0XN37	—	0.983	B0XN37 →
E3QCU0	—	0.983	E3QCU0 →